AnaptysBio stock whipsawed Wednesday despite promising results for its experimental rheumatoid arthritis treatment.

AnaptysBio may have ended last year on a low, but 2025 is looking up with the news that its PD-1 agonist rosnilimab has ...

AnaptysBio’s Phase IIb trial of its rheumatoid arthritis (RA) treatment, rosinilimab, has seen some patients achieve the ...

Monoclonal antibodies are novel therapeutic agents used with great success in the treatment of rheumatoid arthritis (RA ... concomitant medications and illnesses, dates of studies performed ...

Rheumatoid arthritis (RA) is an autoimmune disorder affecting millions worldwide, causing chronic inflammation, debilitating ...

Among small-molecule drugs, upadacitinib and deucravacitinib demonstrate the best efficacy for treatment of psoriatic ...

Gene therapies to treat rheumatoid arthritis have evolved slowly, but one is ready to move into human trials and an ...

Researchers at CeMM and the Medical University of Vienna have developed an innovative microscopy-based approach that could predict the best approved drug to treat individual rheumatoid arthritis ...

This article helps to dispel myths related to rheumatoid arthritis (RA) and raise awareness regarding it. From causes to ...

Also: AI agents may soon surpass people as primary application users The first breakthrough of the year-long collaboration is the potential capability to predict drug response from patients with ...

Intermittent fasting may benefit antioxidant and inflammatory markers in postmenopausal women with rheumatoid arthritis, according to a study published online Jan. 18 in Scientific Reports.

While you wait for the groundhog to make his determination this weekend, take some time to buff up your knowledge of ...